Evaluation of the effect of 6 months treatment with V0191 on symptoms changes in patients with Mild Cognitive Impairment. Multicentre, randomised, double-blind, placebo-controlled study in parallel groups.
Phase of Trial: Phase II
Latest Information Update: 23 Nov 2013
At a glance
- Drugs V 0191 (Primary)
- Indications Mild cognitive impairment
- Focus Therapeutic Use
- 16 Nov 2013 Planned number of patients changed from 210 to 200 as reported by European Clinical Trials Database.
- 03 Jul 2012 Planned number of patients changed from 200 to 210 as reported by European Clinical Trials Database.
- 19 Aug 2011 The trial was completed in Finland on 7 January 2010 and in Austria on 4 December 2009, according to the European Clinical Trials Database.